Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Transfer Part of R&D Function to Subsidiary
September 12, 2011
- Takeda Begins Domestic PII Clinical Trials for Leuplin Successor TAK-385
September 12, 2011
- Medinet Granted Patent on Cancer Antigen Peptide in 11 European Countries
September 12, 2011
- Helsinn Initiates Global PIII Program for Anamorelin
September 12, 2011
- Takara Bio to Supply Plasmid Vectors for iPS Cell Production to Kyoto University
September 12, 2011
- JAK Inhibitor May Be as Effective as Biologics at Lower Cost: Prof. Takeuchi of Keio University
September 12, 2011
- Tablet Terminals Effective for Changing Doctors’ Prescribing Behavior: M3
September 12, 2011
- MTPC Applies for DPP-4 Inhibitor Teneligliptin
September 12, 2011
- Toyama Chemical, Eisai Resubmit NDA for RA Treatment T-614
September 12, 2011
- Pfizer’s Novel NSCLC Treatment Crizotinib Receives Approval in US
September 12, 2011
- Bayer’s Alpharadin to Be Granted Fast Track Review Status from FDA
September 12, 2011
- Ethical Drugs Sales Rise 5.3% in 2nd Quarter: IMS Japan
September 12, 2011
- PIII Trial for Type 2 Diabetes Treatment SYR-472 Started in Japan: Takeda
September 9, 2011
- Afinitor Approved for Pancreatic NET in Europe: Novartis
September 9, 2011
- Takeda to Invest ¥5 Bil. on Electric Power Facility
September 9, 2011
- Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
- Eplerenone significantly Reduces Cardiovascular Death in High-Risk CHF Patients: Pfizer
September 7, 2011
- MTPC to Reorganize Its Subsidiary
September 7, 2011
- ASKA to Initiate Transparency GL Project on Full Scale in October
September 7, 2011
- Tarceva Approved for 1st-line in NSCLC: Roche
September 6, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…